Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06056804
- Locations
- 🇨🇳
Beijing Friendship Hospital,Capital Medical University, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
- Conditions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Target Recruit Count
- 60
- Registration Number
- NCT06034964
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT06032845
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06030258
- Locations
- 🇨🇳
Shandong Province Cancer Hospital, Jinan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, China
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Yong Zhang,MD
- Target Recruit Count
- 48
- Registration Number
- NCT06017583
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 118
- Registration Number
- NCT06010303
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇹🇭Songklanagarind Hospital (Prince of Songkhla University), Hat Yai, Thailand
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
- Conditions
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Peking University Hospital of Stomatology
- Target Recruit Count
- 110
- Registration Number
- NCT06009861
- Locations
- 🇨🇳
Shanxi Cancer hospital, Taiyuan, Shanxi, China
🇨🇳Peking University School and Hospital Stomatology, Beijing, Beijing, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Akeso
- Target Recruit Count
- 642
- Registration Number
- NCT05990127
- Locations
- 🇨🇳
The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Cancer hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, Beijing, China
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Target Recruit Count
- 50
- Registration Number
- NCT05984342
- Locations
- 🇨🇳
Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 10
- Registration Number
- NCT05984602
- Locations
- 🇺🇸
NYU Langone Ambulatory Care Center East 38th Street, New York, New York, United States
🇺🇸Ambulatory Care Center, New York, New York, United States
🇺🇸Clinical Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.